CALZ.F Stock Overview
Designs, manufactures, and sells biodegradable medical devices in the United States, Australia, New Zealand, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
PolyNovo Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$1.50 |
| 52 Week High | AU$1.80 |
| 52 Week Low | AU$0.51 |
| Beta | 1.72 |
| 11 Month Change | 15.38% |
| 3 Month Change | -4.95% |
| 1 Year Change | 188.46% |
| 33 Year Change | 3.45% |
| 5 Year Change | 22.95% |
| Change since IPO | 114.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| CALZ.F | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 14.5% | 0.8% | 0.5% |
| 1Y | 188.5% | 20.5% | 30.7% |
Return vs Industry: CALZ.F exceeded the US Medical Equipment industry which returned 22.5% over the past year.
Return vs Market: CALZ.F exceeded the US Market which returned 32.3% over the past year.
Price Volatility
| CALZ.F volatility | |
|---|---|
| CALZ.F Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 8.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CALZ.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine CALZ.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 254 | Swami Raote | polynovo.com |
PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in the United States, Australia, New Zealand, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, a dermal scaffold for the regeneration of the dermis when lost through extensive surgery, trauma, or burn. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; NovoSorb Dermal Beta Cell, a novel intracutaneous ectopic pancreas to treat type 1 diabetes; NovoSorb MTX for single stage grafting in burns, chronic, and surgical wounds; and plastics and reconstructive device products.
PolyNovo Limited Fundamentals Summary
| CALZ.F fundamental statistics | |
|---|---|
| Market cap | US$969.99m |
| Earnings (TTM) | US$3.42m |
| Revenue (TTM) | US$67.11m |
283.6x
P/E Ratio14.5x
P/S RatioIs CALZ.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CALZ.F income statement (TTM) | |
|---|---|
| Revenue | AU$103.23m |
| Cost of Revenue | AU$16.41m |
| Gross Profit | AU$86.82m |
| Other Expenses | AU$81.56m |
| Earnings | AU$5.26m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.0076 |
| Gross Margin | 84.11% |
| Net Profit Margin | 5.10% |
| Debt/Equity Ratio | 3.6% |
How did CALZ.F perform over the long term?
See historical performance and comparison